Abstract
The reprogramming of somatic cells into induced pluripotent stem cells or iPS cells can be achieved by the ectopic expression of defined factors. Patient-specific iPS cell lines can be derived and used for disease modeling, drug and toxicology screening, cellular replacement therapies and basic research. However, reprogramming is slow and inefficient and numerous methods have been described aiming to improve this process. These methods include screening for new genetic factors and chemical compounds, and the engineering of new synthetic factors. Here, we review recent progress made in this field and show how a better understanding of the ES (embryonic stem) cell transcriptional network is important for efficient reprogramming.
Keywords: ES, iPS, pluripotency, reprogramming, self-renewal, transcriptionnal networks.
Current Molecular Medicine
Title:Pluripotency-Regulating Networks Provide Basis for Reprogramming
Volume: 13 Issue: 5
Author(s): I. Aksoy and L.W. Stanton
Affiliation:
Keywords: ES, iPS, pluripotency, reprogramming, self-renewal, transcriptionnal networks.
Abstract: The reprogramming of somatic cells into induced pluripotent stem cells or iPS cells can be achieved by the ectopic expression of defined factors. Patient-specific iPS cell lines can be derived and used for disease modeling, drug and toxicology screening, cellular replacement therapies and basic research. However, reprogramming is slow and inefficient and numerous methods have been described aiming to improve this process. These methods include screening for new genetic factors and chemical compounds, and the engineering of new synthetic factors. Here, we review recent progress made in this field and show how a better understanding of the ES (embryonic stem) cell transcriptional network is important for efficient reprogramming.
Export Options
About this article
Cite this article as:
Aksoy I. and Stanton L.W., Pluripotency-Regulating Networks Provide Basis for Reprogramming, Current Molecular Medicine 2013; 13(5) . https://dx.doi.org/10.2174/1566524011313050002
DOI https://dx.doi.org/10.2174/1566524011313050002 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Multidrug Transporters as Drug Targets
Current Drug Targets Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends
Current Topics in Medicinal Chemistry Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry RNA Interference (RNAi) Patents and Human Health Related Applications of RNAi
Recent Patents on DNA & Gene Sequences Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Hsp70 Structure, Function, Regulation and Influence on Yeast Prions
Protein & Peptide Letters Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Current Clinical Pharmacology Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects
Recent Patents on Anti-Cancer Drug Discovery Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews